Skip to main content

Table 2 Summary of antipurinergic therapy results in the Fragile X mouse model of autism spectrum disorders

From: Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model

Feature

Abnormality in Fragile X males vs. FVB controls

Response to antipurinergic therapy

Social preference

Decreased

Normalized (P <0.05)

Social novelty

Decreased

Normalized (P <0.05)

T-maze spontaneous alternation

Decreased

Normalized (P <0.001)

Marble burying

Decreased

Normalized (P <0.05)

Core body temperature

Decreased

Normalized (P <0.001)

Acoustic startle

Decreased [sic]

Unchanged (P = ns)

Metabolomics (60 pathways measured)

20 of 60 pathways disturbed

33 metabolites increased and 25 decreased of 58 changed

Synaptosomal structure by electron microscopy

Fragile and malformed post-synaptic densities; Accumulation of electron dense matrix material

Improved

Synaptosomal proteins (54 interrogated)

N/A

17 proteins were changed (for example, decreased PI3/GSK3β, GluR1, C1q, and APP; increased PPARβ/δ)

Locomotor activity - total distance (hyperactivity), center exploration, holepokes, rearing

None

N/A